Based on an established but pragmatic definition of cancer family syndrome as the presence of three or more relatives affected by colorectal cancer in a first degree kinship, the contribution of this syndrome to the total cancer burden in Northern Ireland has been studied by investigating all non-polyposis probands under 55 years old at histological diagnosis between 1976 and 1978 To date, efforts to reduce mortality from colorectal cancer through mass screening have had limited success and despite the recruitment of over 250 000 participants in five large controlled trials, a mortality reduction in the groups assigned to screening has yet to be shown.' Doubt has also been expressed about the value of sigmoidoscopic surveillance for polyps in asymptomatic average risk patients.2 A targeted approach, on the other hand, might increase the yield and cost effectiveness of screening threefold3 if directed towards the 15% of patients with discernible risk factors.4 It has been suggested that cancer family syndrome (or hereditary non-polyposis colorectal cancer) overshadows all other predisposing conditions and constitutes the majority of this group for whom earlier diagnosis through screening is thought possible.'
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Cancer family syndrome, a putatively autosomal dominant condition well reviewed by Lynch, 6 is characterised in most reports by an early age of onset (40-45 years), a proximal tumour excess, a high risk of metachronous disease, and an excess of other adenocarcinomas in the kinship. There have, however, been relatively few attempts to determine the prevalence and features of this condition in defined populations,7-9 and its frequency in the United Kingdom has not previously been reported. The lack of a useful biomarker for the condition has hindered its documentation in both family studies and in population surveys and consequently, for the purposes of epidemiological comparison, the syndrome has had to be defined pragmatically. '°N evertheless, the population context is preeminent among the factors that will determine the predictive utility of any biomarker." Thus more population based studies of the epidemiology of this condition are needed if the role of targeted screening for colorectal cancer is to be adequately assessed.
There are some advantages to studying this syndrome in Northern Ireland. The population is the most ethnically homogeneous in the United Kingdom,'2 the mean family size is larger, and the proportion of illegitimate births is lower than in the rest of Britain.'3 Also, the incidence and mortality from colorectal cancer in the province is the highest in the British Isles. 141" We therefore report the first population based study of the prevalence and principal characteristics of cancer family syndrome in the United Kingdom. 32 Undoubtedly the issue of genetic heterogeneity in cancer family syndrome will ultimately have to be resolved in the laboratory, but the predictive utility ofany putative biomarker is unlikely to be assured unless the population context of ascertained families and their clinical features is adequately described." Although this is one of the largest and most highly verified family studies of its kind, there is an obvious need for more population based research if the potential for a more successfully targeted screening programme is ever to be realised.
Patients and methods

PATIENTS
2 (0) Small bowel 1 (0) 1 (0) 0 (0) Biliary tree 3 (0) 1 (0) 0 (0) Pancreas 11 (0) 1 (0) 0 (0) Larynx 1 (0) 0 (0) 0 -(0) Lung 27 (2) 8 (0) 2 (1) Skin 3 (4) 0 (1) 1 (2) Breast 11 (1) 2 (1) 1 (0) Cervix/uterus 19 (0) 4 (0) 1 (0) Ovary 2 (0) 0 (0) 0 (0) Vagina 2 (0) 0 (0) 0 (0) Prostate 3 (1) 0 (1) 0 (0) Bladder/kidney 6 (0) 2 (0) 1 (0) Secondary/unspecified 7 (0) 1 (0) 0 (0) Other 16 (0) 2 (0) 0 (0) *
